Medtronic

Investigators reported that cardiac survival of patients, who were implanted with the 21F CoreValve system in 2005 and 2006, was 77.9 percent at two years and 68 percent at four years; in other Medtronic news, company announces completing the acquisition of Peak Surgical Inc. and Salient Surgical Technologies Inc.

“within a decade, Medtronic’s sales in both China and India could exceed its sales in the U.S” says Medtronic CEO Omar Ishrak

Medtronic Inc. today announced that it has entered into a definitive agreement to acquire PEAK Surgical Inc., a recognized leader in the emerging field of advanced energy surgical incision technology

Medtronic, Inc. today announced that it has settled a patent lawsuit it initiated against W.L. Gore & Associates.

Medtronic, which has been the focus of recent reports detailing its payments to doctors, is defending that practice.

Today, Medtronic, Inc. announces two significant clinical trials related to medical device interventions for stroke.

Data presented today at the EUROPACE 2009 congress on the XPECT clinical trial, sponsored by Medtronic, Inc., shows positive results for the Medtronic Reveal® XT Insertable Cardiac Monitor (ICM).

Today, Medtronic, Inc. announces two significant clinical trials related to medical device interventions for stroke.

Medtronic, Inc. today announced it has received CE Mark for the company’s second-generation pacemaker designed, tested, approved for use as labeled with MRI machines, the Advisa DR MRI™ SureScan™ pacing system.

Through five years following initial implantation in an FDA-approved study, the Talent Abdominal Stent Graft from Medtronic, Inc., demonstrated durable safety and effectiveness in patients with abdominal aortic aneurysms.

Premier Purchasing Partners, LP, today announced new agreements for spinal implants and related products have been awarded to Aesculap Implant Systems Inc. of Center Valley, Pa.; DePuy Spine of Raynham, Mass.; and Medtronic Sofamor Danek of Memphis, Tenn.

Medtronic, Inc. announced new data presented today on the safety and effectiveness of Medtronic’s CoreValve system via a novel, subclavian approach.

Medtronic, Inc. announced completion of enrollment in the TTOP-AF (Tailored Treatment of Permanent Atrial Fibrillation) clinical trial. The study is evaluating the use of the Medtronic Ablation Frontiers Cardiac Ablation System, for the treatment of continuous atrial fibrillation.

Medtronic, Inc., today announced that its Endeavor drug-eluting stent (DES) is the first and only coronary stent to have received CE Mark approval for treating patients with acute coronary syndrome.

MVP® (Managed Ventricular Pacing), exclusive programming on Medtronic pacemakers was applied in the MVP Trial of implantable cardioverter-defibrillator patients.

Medtronic, Inc. today announced completion of enrollment in the TTOP-AF (Tailored Treatment of Permanent Atrial Fibrillation) clinical trial.